RU2745560C2 - 5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака - Google Patents

5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака Download PDF

Info

Publication number
RU2745560C2
RU2745560C2 RU2018108050A RU2018108050A RU2745560C2 RU 2745560 C2 RU2745560 C2 RU 2745560C2 RU 2018108050 A RU2018108050 A RU 2018108050A RU 2018108050 A RU2018108050 A RU 2018108050A RU 2745560 C2 RU2745560 C2 RU 2745560C2
Authority
RU
Russia
Prior art keywords
seq
amino acid
acid sequence
bap049
antibody
Prior art date
Application number
RU2018108050A
Other languages
English (en)
Russian (ru)
Other versions
RU2018108050A3 (ko
RU2018108050A (ru
Inventor
Сэйнела БАЙЛИК
Гомес Хуан Альберто Камачо
Джон Скотт КЭМЕРОН
ЛАРИЯ Хулио Сесар КАСТРО-ПАЛОМИНО
МЛ. Дэнни Роланд ХОВАРД
Original Assignee
Новартис Аг
Палобиофарма, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг, Палобиофарма, С.Л. filed Critical Новартис Аг
Priority claimed from PCT/IB2016/054834 external-priority patent/WO2017025918A1/en
Publication of RU2018108050A publication Critical patent/RU2018108050A/ru
Publication of RU2018108050A3 publication Critical patent/RU2018108050A3/ru
Application granted granted Critical
Publication of RU2745560C2 publication Critical patent/RU2745560C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2018108050A 2015-08-11 2016-08-10 5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака RU2745560C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15382425 2015-08-11
EP15382425.5 2015-08-11
US201662335984P 2016-05-13 2016-05-13
US62/335,984 2016-05-13
PCT/IB2016/054834 WO2017025918A1 (en) 2015-08-11 2016-08-10 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021106602A Division RU2021106602A (ru) 2015-08-11 2016-08-10 5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака

Publications (3)

Publication Number Publication Date
RU2018108050A RU2018108050A (ru) 2019-09-13
RU2018108050A3 RU2018108050A3 (ko) 2020-02-17
RU2745560C2 true RU2745560C2 (ru) 2021-03-29

Family

ID=65563017

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018108050A RU2745560C2 (ru) 2015-08-11 2016-08-10 5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака

Country Status (13)

Country Link
JP (1) JP6964113B2 (ko)
KR (1) KR102226100B1 (ko)
CL (1) CL2018000349A1 (ko)
DK (1) DK3334431T3 (ko)
ES (1) ES2761910T3 (ko)
HK (1) HK1249409B (ko)
HR (1) HRP20192192T1 (ko)
HU (1) HUE046646T2 (ko)
IL (1) IL257350A (ko)
LT (1) LT3334431T (ko)
PT (1) PT3334431T (ko)
RU (1) RU2745560C2 (ko)
ZA (1) ZA201800792B (ko)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021565B1 (ru) * 2010-03-31 2015-07-30 Палобиофарма, С.Л. Производные 4-аминопиримидина как антагонисты аденозинового рецептора a

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021565B1 (ru) * 2010-03-31 2015-07-30 Палобиофарма, С.Л. Производные 4-аминопиримидина как антагонисты аденозинового рецептора a

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKIO OHTA ET AL: "A2A adenosine receptor protects tumors from antitumor T cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, 2006, v. 103, no. 35, p. 13132-13137. *
AKIO OHTA ET AL: "A2A adenosine receptor protects tumors from antitumor T cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, 2006, v. 103, no. 35, p. 13132-13137. BRAHMER J.R., PARDOLL D.M. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res. 2013; 1(2): p.85-91. doi:10.1158/2326-6066.CIR-13-0078. *
BRAHMER J.R., PARDOLL D.M. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res. 2013; 1(2): p.85-91. *
doi:10.1158/2326-6066.CIR-13-0078. *

Also Published As

Publication number Publication date
JP2019218346A (ja) 2019-12-26
IL257350A (en) 2018-03-29
KR102226100B1 (ko) 2021-03-10
KR20200057790A (ko) 2020-05-26
HRP20192192T1 (hr) 2020-03-06
PT3334431T (pt) 2020-01-06
RU2018108050A3 (ko) 2020-02-17
CL2018000349A1 (es) 2018-09-07
HK1249409B (zh) 2020-05-08
ES2761910T3 (es) 2020-05-21
ZA201800792B (en) 2019-06-26
JP6964113B2 (ja) 2021-11-10
LT3334431T (lt) 2019-12-27
DK3334431T3 (da) 2020-01-02
HUE046646T2 (hu) 2020-03-30
RU2018108050A (ru) 2019-09-13

Similar Documents

Publication Publication Date Title
KR102114562B1 (ko) 암의 치료에 사용하기 위한 5-브로모-2,6-디-(1h-피라졸-1-일)피리미딘-4-아민
US11529399B2 (en) Anti-ICOS agonist antibodies and uses thereof
CN109757103B (zh) 针对tim3的抗体及其用途
KR102473028B1 (ko) 항-tim-3 항체 및 조성물
AU2022228155A1 (en) Antibodies to cd40
WO2017017624A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
EA037006B1 (ru) Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
WO2018213297A1 (en) Treatment of cancer with anti-gitr agonist antibodies
WO2021217893A1 (zh) 结合tigit抗原的抗体及其制备方法与应用
AU2017279046A1 (en) Therapeutic uses of a c-Raf inhibitor
AU2016369623A1 (en) Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
EP4375300A1 (en) Pharmaceutical composition and use
RU2745560C2 (ru) 5-бром-2,6-ди-(1н-пиразол-1-ил)пиримидин-4-амин для применения в лечении рака
KR20220131279A (ko) 항lag3단일 클론 항체 및 그 제조 방법과 응용
US20240352153A1 (en) Pharmaceutical composition and use
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
KR20240017054A (ko) 항-icos 항체를 사용한 pd-l1 음성 또는 저발현 암의 치료
CN117460529A (zh) 抗icos抗体的用途
EA041306B1 (ru) Агонистические антитела против icos и их применение